Privacy Policy

Intro

PV Watch Daily is committed to publishing clear, timely, responsible, and professionally relevant coverage of developments across the pharmacovigilance and drug safety landscape. Our goal is to help professionals, employers, researchers, students, and other stakeholders stay informed on the issues shaping pharmacovigilance, regulatory oversight, safety monitoring, compliance, and industry practice.

This editorial policy explains how we approach content, sourcing, analysis, accuracy, and corrections.

Our Editorial Mission

PV Watch Daily exists to provide trustworthy coverage of:

  • pharmacovigilance news
  • drug safety developments
  • regulatory updates
  • safety signals
  • inspections and compliance issues
  • AI and digital transformation in PV
  • recalls and quality-related developments
  • career and industry trends

We aim to help readers quickly understand what is happening, why it matters, and how it may affect pharmacovigilance practice, oversight, systems, and professional decision-making.

Our Editorial Principles

1. Accuracy

We strive to publish content that is factually accurate, clearly written, and grounded in credible source material. We aim to distinguish carefully between:

  • verified facts
  • official regulatory statements
  • publicly available reports
  • commentary or analysis
  • reasonable inference

Where a post includes analysis or interpretation, we aim to make that clear in the writing.

2. Relevance

We focus on developments that are materially relevant to pharmacovigilance, drug safety, regulatory affairs, compliance, risk management, or related life sciences functions.

3. Clarity

We seek to explain complex issues in a way that is useful to professionals while still being accessible to broader readers with an interest in the field.

4. Responsibility

Because pharmacovigilance is a highly regulated and safety-sensitive field, we aim to avoid sensationalism, unnecessary exaggeration, or misleading framing.

5. Professional Integrity

We do not aim to inflame industry controversy for attention. Our priority is informed, responsible coverage that supports understanding and professional awareness.

Sources and Research Standards

PV Watch Daily may draw from a range of source types, including:

  • official regulatory agency websites
  • public safety communications
  • regulatory guidance documents
  • formal meeting highlights and minutes
  • recall notices and alert bulletins
  • public company announcements
  • major industry publications
  • reputable news organizations
  • public domain training and regulatory materials

Whenever possible, we prioritize official and primary sources over secondary commentary.

Where appropriate, we may also reference broader industry reporting to highlight trends or context, especially when discussing market shifts, business developments, or industry practices.

Analysis and Commentary

Some PV Watch Daily articles are straight news reports. Others include commentary, industry interpretation, or analysis.

In analytical or opinion-style pieces, we may draw practical inferences about what a development could mean for:

  • pharmacovigilance teams
  • employers
  • recruiters
  • service providers
  • regulated companies
  • industry professionals

Where we make such inferences, we aim to keep them grounded, transparent, and proportionate to the underlying facts.

Use of Categories

Our content may appear under categories such as:

  • News
  • Regulatory Updates
  • Safety Signals
  • Inspections & Compliance
  • AI & Digital PV
  • Explainers
  • Careers
  • Opinion & Analysis
  • Global Watch
  • Weekly Roundup

These categories are intended to help readers understand the style and purpose of each article.

For example:

  • News typically focuses on reporting recent developments
  • Explainers focus on clarity and understanding
  • Opinion & Analysis includes interpretation and perspective
  • Weekly Roundup summarizes recent notable items

Corrections and Updates

We are committed to correcting significant factual errors when identified.

If a published article contains a material inaccuracy, we may:

  • correct the text
  • update the article for clarity
  • add an editor’s note where appropriate

Because regulatory and safety information can evolve over time, some articles may also be updated when new official information becomes available.

Editorial Independence

PV Watch Daily aims to maintain editorial independence in how content is selected, written, and published.

Editorial decisions are guided by relevance, accuracy, and value to readers — not by pressure from external organizations, employers, service providers, or commercial interests.

If sponsored content, partnership content, or promotional material is ever published, it should be clearly identified as such.

Not Medical or Legal Advice

PV Watch Daily is an industry news and intelligence platform. Our content is provided for informational and editorial purposes only.

Nothing on this website should be interpreted as:

  • medical advice
  • legal advice
  • regulatory advice
  • clinical decision guidance
  • formal pharmacovigilance consulting advice

Readers should consult qualified professionals, official regulators, legal counsel, or internal compliance teams where appropriate.

Reader Trust

Trust is central to pharmacovigilance, and it is central to our editorial approach as well.

We recognize that the drug safety field depends on competence, transparency, process integrity, and careful judgment. We seek to reflect those same values in how we report and communicate.

Contact for Editorial Concerns

If you believe an article requires correction, clarification, or review, please contact us through our Contact page.